These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 16344918)

  • 21. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas.
    Ferreri AJ; Guerra E; Regazzi M; Pasini F; Ambrosetti A; Pivnik A; Gubkin A; Calderoni A; Spina M; Brandes A; Ferrarese F; Rognone A; Govi S; Dell'Oro S; Locatelli M; Villa E; Reni M
    Br J Cancer; 2004 Jan; 90(2):353-8. PubMed ID: 14735176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis.
    Fang Y; Su N; Ma S; Cai J; Zhong L; Li W; Huang H; Li Z; Huang H; Xia Y; Liu P; Guo L; Li Z; Wu Y; Tian X; Wang J; Zhang Y; Cai Q
    Ann Hematol; 2022 Mar; 101(3):595-605. PubMed ID: 34985557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
    Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
    Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urine volume to hydration volume ratio is associated with pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma.
    Isono T; Hira D; Morikochi A; Fukami T; Ueshima S; Nozaki K; Terada T; Morita SY
    Pharmacol Res Perspect; 2021 Dec; 9(6):e00883. PubMed ID: 34664791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leukocytoclastic Vasculitis and Desensitization to High-dose Methotrexate in Primary Central Nervous System Lymphoma.
    Hanna C; Villa D; Irani C; Ghosn M; El Rassy E
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):e197-e200. PubMed ID: 29605422
    [No Abstract]   [Full Text] [Related]  

  • 26. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen.
    Fizazi K; Asselain B; Vincent-Salomon A; Jouve M; Dieras V; Palangie T; Beuzeboc P; Dorval T; Pouillart P
    Cancer; 1996 Apr; 77(7):1315-23. PubMed ID: 8608509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CNS-directed therapy in young children with T-lineage acute lymphoblastic leukemia: High-dose methotrexate versus cranial irradiation.
    Nathan PC; Maze R; Spiegler B; Greenberg ML; Weitzman S; Hitzler JK
    Pediatr Blood Cancer; 2004 Jan; 42(1):24-9. PubMed ID: 14752790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
    Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
    Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma.
    Joerger M; Huitema AD; Illerhaus G; Ferreri AJ
    Leuk Lymphoma; 2012 Oct; 53(10):1867-75. PubMed ID: 22530664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
    Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
    Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
    Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer.
    Guardiola E; Peyrade F; Chaigneau L; Cupissol D; Tchiknavorian X; Bompas E; Madroszyk A; Ronchin P; Schneider M; Bleuze JP; Blay JY; Pivot X
    Eur J Cancer; 2004 Sep; 40(14):2071-6. PubMed ID: 15341981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methotrexate treatment of advanced head and neck cancers: a dose response evaluation.
    Woods RL; Fox RM; Tattersall MH
    Cancer Treat Rep; 1981; 65 Suppl 1():155-9. PubMed ID: 7034929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose methotrexate for primary CNS lymphoma in the elderly.
    Ng S; Rosenthal MA; Ashley D; Cher L
    Neuro Oncol; 2000 Jan; 2(1):40-4. PubMed ID: 11302253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
    Green MR; Chowdhary S; Lombardi KM; Chalmers LM; Chamberlain M
    Expert Rev Neurother; 2006 May; 6(5):635-52. PubMed ID: 16734512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Chemotherapy with MTX, 5-FU and CDGP for treatment of newly diagnosed head and neck cancer].
    Sakoda T; Morizane R; Nakahara K; Enomoto Y; Nosaka A; Enomoto T; Kitano H
    Gan To Kagaku Ryoho; 2009 Sep; 36(9):1451-5. PubMed ID: 19755812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
    Hoang-Xuan K; Taillandier L; Chinot O; Soubeyran P; Bogdhan U; Hildebrand J; Frenay M; De Beule N; Delattre JY; Baron B;
    J Clin Oncol; 2003 Jul; 21(14):2726-31. PubMed ID: 12860951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose methotrexate for elderly patients with primary CNS lymphoma.
    Zhu JJ; Gerstner ER; Engler DA; Mrugala MM; Nugent W; Nierenberg K; Hochberg FH; Betensky RA; Batchelor TT
    Neuro Oncol; 2009 Apr; 11(2):211-5. PubMed ID: 18757775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.
    Spiegler BJ; Kennedy K; Maze R; Greenberg ML; Weitzman S; Hitzler JK; Nathan PC
    J Clin Oncol; 2006 Aug; 24(24):3858-64. PubMed ID: 16921038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term AIDS-related PCNSL outcomes with HD-MTX and combined antiretroviral therapy.
    Moulignier A; Lamirel C; Picard H; Lebrette MG; Amiel C; Hamidi M; Polivka M; Mikol J; Cochereau I; Pialoux G
    Neurology; 2017 Aug; 89(8):796-804. PubMed ID: 28747447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.